Tumor Genome Profiling: The Way of the Future or TMI?
24.06.2014 / Thomson Reuters Blog
The most frequent argument about whether targeted therapies are worth it is about money â€“ in the crudest terms whether the slim survival benefit of such drugs justifies their fat price tag. The American Society of Clinical Oncology (ASCO) 2014 has declared value to be one theme of this yearâ€™s annual meeting. But at the […]